MX2019010797A - Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. - Google Patents
Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.Info
- Publication number
- MX2019010797A MX2019010797A MX2019010797A MX2019010797A MX2019010797A MX 2019010797 A MX2019010797 A MX 2019010797A MX 2019010797 A MX2019010797 A MX 2019010797A MX 2019010797 A MX2019010797 A MX 2019010797A MX 2019010797 A MX2019010797 A MX 2019010797A
- Authority
- MX
- Mexico
- Prior art keywords
- alone
- combination
- cancer
- oncolytic viruses
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere al uso de virus oncolíticos (por ejemplo, talimogén laherparepvec), solos o en combinación con inhibidores de punto de control inmunitario (por ejemplo, compuestos anti-CTLA-4, anti-PD-1 y anti-PD-L1 tales como un anticuerpo) para el tratamiento de diversos tipos de cáncer. Además, la presente invención se refiere a composiciones y kits relacionados con dichos usos de virus oncolíticos, solos o en combinación con inhibidores de punto de control inmunitario.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471875P | 2017-03-15 | 2017-03-15 | |
PCT/US2018/022442 WO2018170133A1 (en) | 2017-03-15 | 2018-03-14 | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019010797A true MX2019010797A (es) | 2019-10-24 |
Family
ID=61913527
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010797A MX2019010797A (es) | 2017-03-15 | 2018-03-14 | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. |
MX2024006614A MX2024006614A (es) | 2017-03-15 | 2019-09-11 | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2024006614A MX2024006614A (es) | 2017-03-15 | 2019-09-11 | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200009204A1 (es) |
EP (1) | EP3595690A1 (es) |
JP (2) | JP2020510050A (es) |
CN (1) | CN110461346A (es) |
AU (2) | AU2018235944B2 (es) |
CA (1) | CA3056392A1 (es) |
MA (1) | MA51630A (es) |
MX (2) | MX2019010797A (es) |
WO (1) | WO2018170133A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3381942T (pt) * | 2012-08-30 | 2021-05-24 | Amgen Inc | Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário |
EP3664844A1 (en) * | 2017-08-07 | 2020-06-17 | Amgen Inc. | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus |
CN116870165A (zh) * | 2018-08-17 | 2023-10-13 | 北京奥源和力生物技术有限公司 | 用于治疗癌症的组合及其治疗用途 |
CN116802278A (zh) * | 2020-09-18 | 2023-09-22 | 成都美杰赛尔生物科技有限公司 | 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤 |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
EP4332218A4 (en) | 2021-06-03 | 2024-09-18 | Shanghai Yunying Biopharmaceutical Tech Co Ltd | ONCOLYTIC VIRUS VECTOR AND ITS USE |
TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
CN115463161A (zh) * | 2022-09-15 | 2022-12-13 | 广东天普生化医药股份有限公司 | 一种溶瘤病毒在制备治疗骨肉瘤的药物组合物中的应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
JP2003535565A (ja) | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
WO2000054795A1 (en) | 1999-03-15 | 2000-09-21 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
ATE312189T1 (de) | 2000-01-21 | 2005-12-15 | Biovex Ltd | Virusstämme für die onkolytische behandlung von krebs |
CN1286303A (zh) | 2000-08-17 | 2001-03-07 | 上海市农业科学院生物技术研究中心 | 抗人龋齿致病菌蛋白基因及其制备方法 |
JP4212897B2 (ja) | 2001-03-27 | 2009-01-21 | 具紀 藤堂 | ウイルスおよび治療法におけるそれらの使用 |
JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
PT2753355T (pt) | 2011-09-08 | 2019-02-01 | Univ New York | Vírus herpes simplex oncolítico e suas utilizações terapêuticas |
PT3381942T (pt) * | 2012-08-30 | 2021-05-24 | Amgen Inc | Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
DK3169340T3 (da) * | 2014-07-16 | 2020-11-09 | Roussy Inst Gustave | Kombination af onkolytisk virus med immun-checkpoint-modulatorer |
WO2017013419A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
EP3402500A4 (en) * | 2016-01-11 | 2019-06-12 | Turnstone Limited Partnership | COMBINATION THERAPY OF ONCOLYTIC VIRUS AND CHECKPOINT INHIBITOR |
WO2017156349A1 (en) * | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
WO2018115458A1 (en) * | 2016-12-23 | 2018-06-28 | Virttu Biologics Limited | Treatment of cancer |
-
2018
- 2018-03-14 AU AU2018235944A patent/AU2018235944B2/en active Active
- 2018-03-14 MA MA051630A patent/MA51630A/fr unknown
- 2018-03-14 CA CA3056392A patent/CA3056392A1/en active Pending
- 2018-03-14 WO PCT/US2018/022442 patent/WO2018170133A1/en unknown
- 2018-03-14 MX MX2019010797A patent/MX2019010797A/es unknown
- 2018-03-14 JP JP2019549569A patent/JP2020510050A/ja active Pending
- 2018-03-14 EP EP18716700.2A patent/EP3595690A1/en active Pending
- 2018-03-14 CN CN201880017970.9A patent/CN110461346A/zh active Pending
- 2018-03-14 US US16/493,376 patent/US20200009204A1/en active Pending
-
2019
- 2019-09-11 MX MX2024006614A patent/MX2024006614A/es unknown
-
2023
- 2023-04-14 JP JP2023066170A patent/JP2023089171A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202086A patent/AU2024202086A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2018235944B2 (en) | 2024-01-04 |
MX2024006614A (es) | 2024-06-19 |
CN110461346A (zh) | 2019-11-15 |
AU2024202086A1 (en) | 2024-04-18 |
AU2018235944A1 (en) | 2019-09-26 |
JP2020510050A (ja) | 2020-04-02 |
US20200009204A1 (en) | 2020-01-09 |
WO2018170133A1 (en) | 2018-09-20 |
JP2023089171A (ja) | 2023-06-27 |
CA3056392A1 (en) | 2018-09-20 |
MA51630A (fr) | 2020-01-22 |
EP3595690A1 (en) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2024006614A (es) | Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer. | |
MX2024005976A (es) | Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer. | |
WO2018234793A3 (en) | Antibodies | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
TR201901445T4 (tr) | Il2rbeta/yaygın gamma zinciri antikorları. | |
MX2018016364A (es) | Anticuerpos anti-pd-l1. | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
WO2017164678A3 (ko) | 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도 | |
MX2016009047A (es) | Anticuerpos dirigidos contra interleucina-33 (il-33). | |
EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
MX2018003713A (es) | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). | |
MX2019002728A (es) | Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. | |
MX2019005089A (es) | Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso. | |
NZ729395A (en) | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody | |
EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
MX2021010458A (es) | Uso de virus oncoliticos para el tratamiento del cancer. | |
MX2021005686A (es) | Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer. | |
MX2021000786A (es) | Receptor para supresor de ig del dominio v de activación de células t (vista). | |
MX2018009218A (es) | Anticuerpos de cgrp y sus usos. |